Ranking Invest
Switch to English

Viking Therapeutics, Inc.

Segmento: Healthcare Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Indicadores Básicos

Valor de Mercado

$ 2.74 Bi

IVR

-

IVR2

-0.12

Índices de Previsibilidade

Faturamento

0.00

Lucro

0.14

Margem

0.00

Índices de Tendência

Faturamento

0.00

Lucro

-10.24

Margem

0.00

Índices de Endividamento

DIV/PAT

-0.04

DIV/L4T

0.29

Dívida Líquida

-$ 36.94 Mi

Patrimônio Líquido

$ 846.92 Mi

L4T

-$ 128.24 Mi

MM4T

0.00%

Dívidas
Gráfico Lucro/Faturamento X Trimestre